Bausch Health (BHC) and its Salix Pharmaceuticals unit acknowledged Friday the inclusion of Xifaxan 550 milligram tablets in the second round of price negotiations under the Inflation Reduction Act.

Bausch Health and Salix said they look forward to the discussions with the US Department of Health and Human Services' Centers for Medicare and Medicaid Services, or CMS.

In a separate statement, CMS said negotiations will be conducted this year and any negotiated prices will take effect in 2027.

Drug companies with a selected drug for price negotiations have until Feb. 28 to decide on their participation in the talks, according to the statement.

Price: 7.63, Change: -0.02, Percent Change: -0.26